ClinicalTrials.gg
CompletedNCT03707717Updated Jun 16, 2020

A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants

A Phase 1 interventional study of Bimekizumab in Healthy Volunteers, sponsored by UCB Biopharma S.P.R.L.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-16.

Sponsored by UCB Biopharma S.P.R.L. (part of UCB S.A.) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2019, 7 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the pharmakokinetics (PK), safety, tolerability, and immunogenicity of bimekizumab (BKZ) when administered subcutaneously (sc) via 3 different BKZ delivery devices in healthy participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • BKZ
  • UCB4940
  • Auto-Injector
  • Healthy Participants
03

In context

Lead sponsor

UCB Biopharma S.P.R.L. is the lead sponsor of 48 studies on the registry; none are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 12 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is male or female aged >=18 years and \<=55 years at Screening Visit
  • Participant must be in good health (physically and mentally) as determined by the Investigator based on medical history (any chronic and acute illness), physical examination, vital signs, 12-lead (ECG), and laboratory screening tests during the Screening Period
  • Participant has a (BMI) of 18-32 kg/m2 and a minimum body weight of 50 kg for male participants and 45 kg for female participants, and a maximum body weight of 100 kg for all participants
  • Participant is willing to abstain from alcohol-, tobacco-, and caffeine-containing products for 48 h prior to admission into the clinic and during the entire in-clinic stay

Exclusion criteria

Exclusion Criteria:

  • Subject has an active infection (except common cold), a serious infection, or a history of opportunistic, recurrent or chronic infections
  • Participant has a history of a positive tuberculosis (TB) test or evidence of possible TB or latent TB infection at Screening Visit
  • Participant has concurrent acute or chronic viral or C or (HIV) infection
  • Female participant who is pregnant, or plans to become pregnant during the study, or lactating, or sexually active with who is not using a medically accepted method
  • Participants receiving any live (includes attenuated) vaccination within the 8 weeks prior to Screening visit (eg, inactivated influenza and pneumococcal vaccines are allowed but nasal influenza vaccination is not permitted). are not allowed during the study or for 20 weeks after the last dose of the IMP
  • Participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's ability to participate in this study
  • Participant has active neoplastic disease or history of neoplastic disease within 5 years of Screening Visit (except for basal or squamous cell carcinoma of the skin or carcinoma in situ that has been definitively treated with standard of care)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
189 participants (actual)

Study arms

  • Experimental
    Bimekizumab-SS

    Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a prefilled syringe.

    Drug: Bimekizumab

  • Experimental
    Bimekizumab-AI

    Subjects randomized to this arm will receive bimekizumab administered subcutaneously with an auto-injector.

    Drug: Bimekizumab

  • Experimental
    Bimekizumab-TN

    Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a reference device.

    Drug: Bimekizumab

Interventions

  • Subjects will receive a pre-specified sequence of bimekzumab in the Treatment Period.

    Also known as: BKZ, UCB4940

06

What researchers measure

Primary outcomes

  1. Maximum observed bimekizumab (BKZ) plasma drug concentration (Cmax)

    The Cmax is the maximum plasma drug concentration of BKZ observed from pharmacokinetic samples taken at predefined time points.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  2. Area under the BKZ plasma concentration-time curve from time zero to last quantifiable concentration (AUCt)

    The AUCt is the area under the plasma concentration-time curve from time zero to last quantifiable concentration (AUCt) of BKZ as determined using the linear trapezoidal rule.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  3. Area under the BKZ plasma concentration-time curve from time zero to infinity (AUC)

    The area under the plasma concentration-time curve from time zero to infinity (AUC) of BKZ is calculated as AUC=AUCt+Clast/lambdaz, where Clast is the last quantifiable plasma concentration and λz is the apparent terminal elimination rate constant.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  4. Percentage of subjects with at least one Adverse Event (AE) from first bimekizumab (BKZ) dose up to Safety Follow Up

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From Baseline to Safety Follow Up (up to Day 140)

  5. Percentage of subjects with at least one Serious Adverse Event (SAE) from first bimekizumab (BKZ) dose up to Safety Follow Up

    A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalization or prolongation of existing hospitalization * Is a congenital anomaly or birth defect * Is as infection that requires treatment parenteral antibiotics * Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above

    Time frame: From Baseline to Safety Follow Up (up to Day 140)

Secondary outcomes

  1. Percentage of the AUC extrapolated from the last quantifiable BKZ plasma concentration (%AUCex)

    The percentage of the AUC extrapolated from the last quantifiable BKZ plasma concentration (Clast) is computed from plasma concentrations of pharmacokinetic samples taken at predefined time points.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  2. Time of occurrence of the maximum observed BKZ plasma drug concentration (tmax)

    Tmax is the time to reach maximum plasma concentration.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  3. Apparent terminal half-life (t1/2)

    Apparent terminal half-life, reported in units of days, as determined via simple linear regression (slope=-lambdaz) of natural log (ln) concentration versus time for data points in the terminal phase of the concentration-time curve. t1/2 is calculated as ln2/lambdaz.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  4. Apparent terminal elimination rate constant (lambdaz)

    The lambdaz is the rate constant of elimination.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  5. Total body plasma clearance for BKZ (CL/F)

    The total body clearance (CL/F) for BKZ will be calculated as Dose/AUC. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  6. Volume of distribution for BKZ (Vz/F)

    Volume of distribution (Vz/F) for BKZ will be calculated as CL/lambdaz.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  7. Time to last quantifiable BKZ plasma concentration (tmin)

    Tmin is the time to last quantifiable plasma concentration for BKZ.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  8. Incidence of Anti-drug-antibodies (ADABs)

    Anti-drug-antibodies (ADABs) will be determined from blood samples taken at predefined timepoints.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

07

Study locations

2 sites
  • Up0033 002
    Baltimore, Maryland 21225, United States
  • Up0033 001
    Berlin, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Jun 2019, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2018
First posted
Oct 16, 2018
StartActual
Oct 15, 2018
Primary completionActual
Jun 5, 2019
CompletionActual
Jun 5, 2019
Last update
Jun 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03707717
Responsible party
Sponsor
First posted
Oct 16, 2018
Start date
Oct 15, 2018
Primary completion
Jun 5, 2019
Completion
Jun 5, 2019
Last update
Jun 16, 2020

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion